Namwin Siourimè Somda, Rabbi Nyarkoh, Abel Tankoano, Ouindgueta Juste Isidore Bonkoungou, Patience B Tetteh-Quarcoo, Eric S Donkor
{"title":"非洲广谱β -内酰胺酶和产碳青霉烯酶志贺氏菌的分子流行病学:系统回顾和荟萃分析。","authors":"Namwin Siourimè Somda, Rabbi Nyarkoh, Abel Tankoano, Ouindgueta Juste Isidore Bonkoungou, Patience B Tetteh-Quarcoo, Eric S Donkor","doi":"10.1186/s12879-024-10266-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The treatment of Shigella infections has become a major challenge due to the emergence of multidrug-resistant Shigella. There is however insufficient knowledge regarding the molecular epidemiology of Shigella strains producing beta-lactamases in Africa. This systematic review investigated the scientific literature on the molecular epidemiology of extended-spectrum beta-lactamase (ESBL) and carbapenemases producing Shigella in Africa.</p><p><strong>Methods: </strong>Papers published in English and French from African countries on the molecular epidemiology of ESBL and carbapenemase producing Shigella from January 1999 to July 5, 2024 were reviewed. An extensive literature search was conducted through electronic databases including PubMed, Scopus, Web of Sciences, African Journals Online (AJOL) and Google scholar using specific keywords. The meta-analysis and forest plots of Shigella species, ESBL and carbapenemases genes were done using the comprehensive Meta-Analysis software. All data were analyzed using a binary random-effects model by the DerSimonian-Laird method at a 95% confidence interval.</p><p><strong>Results: </strong>Out of the 583 research articles, only 18 (3.1%) articles representing eleven countries were included in the meta-analysis. The overall pooled prevalence of ESBL and Carbapenem Resistant (CR)-producing Shigella was estimated as 41.2% (95% CI: 22.8-62.4; I<sup>2</sup> = 93.7%, p < 0.05). The leading ESBL and CR-producing Shigella species reported in this review was Shigella flexneri, 34.5% (95% CI: 16.6-58.2; I<sup>2</sup> = 94.9%, p < 0.05). ESBL and CR-producing Shigella sonnei was the least reported with estimated prevalence of 6.7% (95% CI: 3.4-13.2; I<sup>2</sup> = 80.7%, p < 0.05). In this review, bla<sub>TEM</sub>, bla<sub>OXA-1</sub>, and bla<sub>CTX-M</sub> were the most prevalent genes in Africa with prevalence of 25.9% (95% CI: 13.9-43.2; I<sup>2</sup> = 90.9%, p < 0.05), 25.7% (95% CI: 14.9-43.0; I<sup>2</sup> = 93.7%, p < 0.05), and 10.8% (95% CI: 4.5-23.4; I<sup>2</sup> = 85.6%, p < 0.05) respectively. The prevalence of Carbapenemases genes on the other hand was low, reported as 0.8% (95% CI: 0.2-10.3; I<sup>2</sup> = 51.4%; p < 0.05) for bla<sub>NDM</sub>, 1.1% for bla<sub>KPC</sub>, and 0.5% for bla<sub>IMP</sub>.</p><p><strong>Conclusion: </strong>This study highlighted Shigella flexneri as the most prevalent ESBL and CR-producing Shigella species found in various African countries. The findings from this review indicate bla<sub>TEM</sub>, bla<sub>OXA-1</sub> and bla<sub>CTX-M</sub> as the most prevalent genes in Africa while carbapenemases are least prevalent. The findings from the study suggest that ESBL and CR-producing Shigella pose a significant public health threat in Africa. Effective antimicrobial resistance (AMR) surveillance strategies are needed to improve the management and treatment of Shigella infections in Africa.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"81"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742209/pdf/","citationCount":"0","resultStr":"{\"title\":\"Molecular epidemiology of extended-spectrum beta-lactamases and carbapenemases-producing Shigella in Africa: a systematic review and meta-analysis.\",\"authors\":\"Namwin Siourimè Somda, Rabbi Nyarkoh, Abel Tankoano, Ouindgueta Juste Isidore Bonkoungou, Patience B Tetteh-Quarcoo, Eric S Donkor\",\"doi\":\"10.1186/s12879-024-10266-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The treatment of Shigella infections has become a major challenge due to the emergence of multidrug-resistant Shigella. There is however insufficient knowledge regarding the molecular epidemiology of Shigella strains producing beta-lactamases in Africa. This systematic review investigated the scientific literature on the molecular epidemiology of extended-spectrum beta-lactamase (ESBL) and carbapenemases producing Shigella in Africa.</p><p><strong>Methods: </strong>Papers published in English and French from African countries on the molecular epidemiology of ESBL and carbapenemase producing Shigella from January 1999 to July 5, 2024 were reviewed. An extensive literature search was conducted through electronic databases including PubMed, Scopus, Web of Sciences, African Journals Online (AJOL) and Google scholar using specific keywords. The meta-analysis and forest plots of Shigella species, ESBL and carbapenemases genes were done using the comprehensive Meta-Analysis software. All data were analyzed using a binary random-effects model by the DerSimonian-Laird method at a 95% confidence interval.</p><p><strong>Results: </strong>Out of the 583 research articles, only 18 (3.1%) articles representing eleven countries were included in the meta-analysis. The overall pooled prevalence of ESBL and Carbapenem Resistant (CR)-producing Shigella was estimated as 41.2% (95% CI: 22.8-62.4; I<sup>2</sup> = 93.7%, p < 0.05). The leading ESBL and CR-producing Shigella species reported in this review was Shigella flexneri, 34.5% (95% CI: 16.6-58.2; I<sup>2</sup> = 94.9%, p < 0.05). ESBL and CR-producing Shigella sonnei was the least reported with estimated prevalence of 6.7% (95% CI: 3.4-13.2; I<sup>2</sup> = 80.7%, p < 0.05). In this review, bla<sub>TEM</sub>, bla<sub>OXA-1</sub>, and bla<sub>CTX-M</sub> were the most prevalent genes in Africa with prevalence of 25.9% (95% CI: 13.9-43.2; I<sup>2</sup> = 90.9%, p < 0.05), 25.7% (95% CI: 14.9-43.0; I<sup>2</sup> = 93.7%, p < 0.05), and 10.8% (95% CI: 4.5-23.4; I<sup>2</sup> = 85.6%, p < 0.05) respectively. The prevalence of Carbapenemases genes on the other hand was low, reported as 0.8% (95% CI: 0.2-10.3; I<sup>2</sup> = 51.4%; p < 0.05) for bla<sub>NDM</sub>, 1.1% for bla<sub>KPC</sub>, and 0.5% for bla<sub>IMP</sub>.</p><p><strong>Conclusion: </strong>This study highlighted Shigella flexneri as the most prevalent ESBL and CR-producing Shigella species found in various African countries. The findings from this review indicate bla<sub>TEM</sub>, bla<sub>OXA-1</sub> and bla<sub>CTX-M</sub> as the most prevalent genes in Africa while carbapenemases are least prevalent. The findings from the study suggest that ESBL and CR-producing Shigella pose a significant public health threat in Africa. Effective antimicrobial resistance (AMR) surveillance strategies are needed to improve the management and treatment of Shigella infections in Africa.</p>\",\"PeriodicalId\":8981,\"journal\":{\"name\":\"BMC Infectious Diseases\",\"volume\":\"25 1\",\"pages\":\"81\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-01-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742209/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12879-024-10266-7\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12879-024-10266-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
背景:由于多重耐药志贺氏菌的出现,志贺氏菌感染的治疗已成为一项重大挑战。然而,关于非洲产生β -内酰胺酶的志贺氏菌菌株的分子流行病学知识不足。本系统综述调查了非洲产广谱β -内酰胺酶(ESBL)和碳青霉烯酶的志贺氏菌分子流行病学的科学文献。方法:回顾1999年1月至2024年7月5日非洲国家发表的关于ESBL和产碳青霉烯酶志贺氏菌分子流行病学的英文和法文论文。通过PubMed、Scopus、Web of Sciences、African Journals Online (AJOL)和谷歌scholar等电子数据库进行了广泛的文献检索。采用综合meta分析软件进行志贺氏菌种、ESBL和碳青霉烯酶基因的meta分析和森林图绘制。所有数据采用二元随机效应模型进行分析,采用dersimonan - laird方法,置信区间为95%。结果:在583篇研究文章中,只有18篇(3.1%)代表11个国家的文章被纳入meta分析。ESBL和产碳青霉烯耐药(CR)志贺氏菌的总总患病率估计为41.2% (95% CI: 22.8-62.4;I2 = 93.7%, p 2 = 94.9%, p 2 = 80.7%, p TEM、blaOXA-1和blaCTX-M是非洲最常见的基因,患病率为25.9% (95% CI: 13.9-43.2;I2 = 90.9%, p 2 = 93.7%, p 2 = 85.6%, p 2 = 51.4%;p NDM, blaKPC为1.1%,blaIMP为0.5%。结论:本研究强调了福氏志贺氏菌是在非洲各国发现的最普遍的ESBL和产cr志贺氏菌。本综述的结果表明,在非洲,blaTEM、blaxa -1和blaCTX-M是最普遍的基因,而碳青霉烯酶是最不普遍的基因。这项研究的结果表明,ESBL和产生cr的志贺氏菌在非洲构成了重大的公共卫生威胁。需要有效的抗微生物药物耐药性(AMR)监测战略来改善非洲志贺氏菌感染的管理和治疗。
Molecular epidemiology of extended-spectrum beta-lactamases and carbapenemases-producing Shigella in Africa: a systematic review and meta-analysis.
Background: The treatment of Shigella infections has become a major challenge due to the emergence of multidrug-resistant Shigella. There is however insufficient knowledge regarding the molecular epidemiology of Shigella strains producing beta-lactamases in Africa. This systematic review investigated the scientific literature on the molecular epidemiology of extended-spectrum beta-lactamase (ESBL) and carbapenemases producing Shigella in Africa.
Methods: Papers published in English and French from African countries on the molecular epidemiology of ESBL and carbapenemase producing Shigella from January 1999 to July 5, 2024 were reviewed. An extensive literature search was conducted through electronic databases including PubMed, Scopus, Web of Sciences, African Journals Online (AJOL) and Google scholar using specific keywords. The meta-analysis and forest plots of Shigella species, ESBL and carbapenemases genes were done using the comprehensive Meta-Analysis software. All data were analyzed using a binary random-effects model by the DerSimonian-Laird method at a 95% confidence interval.
Results: Out of the 583 research articles, only 18 (3.1%) articles representing eleven countries were included in the meta-analysis. The overall pooled prevalence of ESBL and Carbapenem Resistant (CR)-producing Shigella was estimated as 41.2% (95% CI: 22.8-62.4; I2 = 93.7%, p < 0.05). The leading ESBL and CR-producing Shigella species reported in this review was Shigella flexneri, 34.5% (95% CI: 16.6-58.2; I2 = 94.9%, p < 0.05). ESBL and CR-producing Shigella sonnei was the least reported with estimated prevalence of 6.7% (95% CI: 3.4-13.2; I2 = 80.7%, p < 0.05). In this review, blaTEM, blaOXA-1, and blaCTX-M were the most prevalent genes in Africa with prevalence of 25.9% (95% CI: 13.9-43.2; I2 = 90.9%, p < 0.05), 25.7% (95% CI: 14.9-43.0; I2 = 93.7%, p < 0.05), and 10.8% (95% CI: 4.5-23.4; I2 = 85.6%, p < 0.05) respectively. The prevalence of Carbapenemases genes on the other hand was low, reported as 0.8% (95% CI: 0.2-10.3; I2 = 51.4%; p < 0.05) for blaNDM, 1.1% for blaKPC, and 0.5% for blaIMP.
Conclusion: This study highlighted Shigella flexneri as the most prevalent ESBL and CR-producing Shigella species found in various African countries. The findings from this review indicate blaTEM, blaOXA-1 and blaCTX-M as the most prevalent genes in Africa while carbapenemases are least prevalent. The findings from the study suggest that ESBL and CR-producing Shigella pose a significant public health threat in Africa. Effective antimicrobial resistance (AMR) surveillance strategies are needed to improve the management and treatment of Shigella infections in Africa.
期刊介绍:
BMC Infectious Diseases is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.